Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
51K characters. Original on sec.gov ·
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for
people with serious diseases, with a focus on specialty markets. We have eight approved medicines: five that treat the
underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, one that treats severe sickle cell disease
(“SCD”) and transfusion dependent beta thalassemia (“TDT”), life shortening inherited blood disorders, one that treats
moderate-to-severe acute pain, and one that treats acromegaly. We are also preparing for the anticipated launch of
povetacicept, a potential treatment for IgA nephropathy (“IgAN”). Our clinical-stage pipeline spans a range of programs
targeting CF, SCD, beta thalassemia, IgAN, neuropathic pain, APOL1-mediated kidney disease, primary membranous
nephropathy, congenital adrenal hyperplasia, adrenocorticotropic hormone-dependent Cushing’s syndrome, autosomal
dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis and myotonic dystrophy type 1, reflecting
our commitment to addressing significant unmet medical needs globally.
Financial Highlights
| Total Revenues | In the third quarter of 2026, our total revenues increased to $3.4 billion as compared to $3.1 billion in the third quarter of 2025, primarily due to continued performance of our CF therapies and growth from diversification into additional disease areas. |
| Cost of Sales | Our cost of sales as a percentage of our net product revenues increased to 15.3% in the third quarter of 2026 as compared to 13.5% in the third quarter of 2025, as a result of changes in product mix and increased intangible asset amortization expense resulting from our acquisition of Crinetics Pharmaceuticals, Inc. (“Crinetics”) in the third quarter of 2026 (the “Crinetics Acquisition”), partially offset by a lower blended royalty rate for our CF medicines. |
| Total R&D, AIPR&D and SG&A Expenses | Our total research and development (“R&D”), acquired in-process research and development expenses (“AIPR&D”) and selling, general and administrative (“SG&A”) expenses increased to $2.2 billion in the third quarter of 2026 as compared to $1.5 billion in the third quarter of 2025, primarily due to approximately $500.0 million of compensation and transaction expenses associated with the Crinetics Acquisition. |
| Cash, Cash Equivalents and Marketable Securities | Our total cash, cash equivalents and marketable securities decreased to $9.8 billion as of September 30, 2026 as compared to $12.3 billion as of December 31, 2025 primarily due to $9.0 billion net cash used to acquire Crinetics and repurchases of our common stock pursuant to our share repurchase program, partially offset by $4.5 billion borrowed pursuant to a term loan (the “2026 Term Loan”) executed in the third quarter of 2026 and cash flows provided by our operating activities. |


Q3 2025
Q3 2026
December 31, 2025
September 30, 2026
Note: Charts above may not add due to rounding.
Business Updates
Marketed Products
Cystic Fibrosis
We expect that the number of people with CF taking our medicines will continue to grow through new approvals and
reimbursement agreements, treatment of younger patients, increased survival and expansion into additional geographies.
Recent progress in activities expanding our CF business is included below:
- In the third quarter of 2026, we secured reimbursement for ALYFTREK in seven additional countries, bringing the
total number of countries where ALYFTREK is reimbursed to 32.
Sickle Cell Disease and Beta Thalassemia
- In the third quarter of 2026, we recorded $99.2 million of CASGEVY product revenues, representing a 30% increase
compared to the second quarter of 2026 and a more than 400% increase compared to the third quarter of 2025.
- The U.S. Food and Drug Administration (the “FDA”) approved CASGEVY in children two years of age and older
with SCD or TDT, making it the first genetic therapy for SCD and TDT indicated for children as young as two years
of age. Since approval, multiple children have initiated treatment.
- In October, the United Arab Emirates and Kingdom of Bahrain approved CASGEVY for the treatment of children 2
years of age and older, and the United Kingdom approved CASGEVY for the treatment of children 5 years of age
and older. We have completed regulatory submissions in the Kingdom of Saudi Arabia (“Saudi Arabia”) for the
treatment of children with SCD or TDT.
Acute Pain
- In the third quarter of 2026, more than 750,000 prescriptions were filled for JOURNAVX across the hospital and
retail settings, representing a more than 40% increase compared to the second quarter of 2026 and more than four
times the 170,000 JOURNAVX prescriptions that were filled in the third quarter of 2025.
- In the third quarter of 2026, we recorded $58.3 million of JOURNAVX product revenues, representing an 18%
increase since the second quarter of 2026, and nearly tripling the $19.6 million of JOURNAVX product revenues in
the third quarter of 2025.
Acromegaly
- PALSONIFY (paltusotine) is a first-in-class, small molecule, once-daily oral somatostatin receptor type 2 agonist
approved in the U.S. for the treatment of adults with acromegaly who had an inadequate response to surgery or for
whom surgery is not an option. Acromegaly is a rare and debilitating condition caused by a benign pituitary tumor
that secretes excess growth hormone. There are an estimated 12,000 adults with acromegaly in the U.S. for whom
PALSONIFY is an option.
- We recorded $10.1 million of PALSONIFY revenue in September 2026, following the closing of the Crinetics
Acquisition on September 1, 2026.
- More than 245 million individuals have access to PALSONIFY, representing approximately 80% of U.S. covered
lives.
- An estimated 3,200 endocrinologists treat the majority of people with acromegaly in the U.S. As of the end of the
third quarter of 2026, approximately 500 of those target specialty endocrinologists are prescribing PALSONIFY.
-
Among patients starting or switching therapy, PALSONIFY has the leading brand share at more than 40%.
-
PALSONIFY was approved in the European Union in April 2026. We expect to begin launches in European markets
in the second half of 2027. The regulatory submission for PALSONIFY in Japan was completed in April 2026, and
the Ministry of Health, Labor and Welfare (the “MHLW”) has granted orphan drug designation in Japan.
Pipeline
We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a
range of modalities. Recent and anticipated progress in activities supporting these efforts is included below:
Cystic Fibrosis
- We have initiated global regulatory submissions for ALYFTREK for the treatment of children with CF two to five
years of age.
Acute and Peripheral Neuropathic Pain
- We expect to complete enrollment in both Phase 3 clinical trials evaluating suzetrigine in diabetic peripheral
neuropathy, a form of peripheral neuropathic pain, by the end of 2026 and expect to share results in mid-2027.
IgA Nephropathy and Other B Cell-Mediated Diseases
- We are developing povetacicept, a dual inhibitor of B cell activating factor (“BAFF”) and a proliferation-inducing
ligand (“APRIL”) cytokines, for multiple diseases. Povetacicept represents a potentially best-in-class approach to
control B cell activity in IgAN.
- The biologics license application for accelerated approval of povetacicept for adults with IgAN is under priority
review by the FDA, with an assigned PDUFA target action date of November 30, 2026. If approved, povetacicept
will become the first commercialized therapy in our emerging nephrology franchise.
- Povetacicept is under review for accelerated approval for adults with IgAN in Saudi Arabia, and the Saudi Food and
Drug Authority has granted Breakthrough designation to povetacicept.
- Povetacicept represents a potentially best-in-class approach to control B cell activity in primary membranous
nephropathy (“pMN”), another B cell-mediated disease. We are enrolling and dosing patients in the Phase 3 portion
of the OLYMPUS Phase 2/3 pivotal trial evaluating povetacicept in people with pMN.
APOL1-Mediated Kidney Disease
- Inaxaplin is our small molecule for the treatment of APOL1-mediated kidney disease (“AMKD”). We have
completed full enrollment in the AMPLITUDE pivotal clinical trial evaluating inaxaplin.
- We are on track to conduct the pre-planned interim analysis for potential U.S. accelerated approval once the interim
analysis cohort has been treated for 48 weeks and to share data from the interim analysis in early 2027.
Rare Endocrine Disorders
- We are developing atumelnant, a once-daily oral adrenocorticotropic hormone (“ACTH”) receptor antagonist, for
the treatment of classic congenital adrenal hyperplasia (“CAH”), which affects approximately 17,000 people in the
U.S. Classic CAH is a rare, chronic, genetic condition in which the adrenal glands are unable to make enough
cortisol. Current therapies force a choice between androgen control and steroid burden, representing a significant
unmet need.
- The Phase 3 clinical trial evaluating atumelnant in adults with CAH is a global, 32-week, randomized, double blind,
placebo-controlled trial of 150 people. Enrollment and dosing are well underway, and we expect to complete
enrollment in the trial in the first quarter of 2027. The FDA, the European Medicines Agency, and the MHLW in
Japan have granted Orphan Drug designation to atumelnant in CAH.
- Atumelnant has demonstrated therapeutic potential in people with ACTH-dependent Cushing’s syndrome, another
serious endocrine disease, which affects more than 10,000 people in the U.S. We have initiated a Phase 2/3 clinical
trial evaluating atumelnant in people with ACTH-dependent Cushing’s syndrome. The FDA has granted Orphan
Drug designation to atumelnant in ACTH-dependent Cushing’s syndrome.
Type 1 Diabetes
- We are enrolling and dosing patients in a Phase 1/2 clinical trial to evaluate the safety and efficacy of VX-017 in
people with type 1 diabetes (“T1D”). VX-017 is an allogeneic, stem cell-derived, fully differentiated islet cell
therapy designed to treat the targeted patient population with T1D regardless of blood type.
- Given the rapid progress of VX-017, we have decided to focus on accelerating the development of VX-017, which
has the potential to reach more people than zimislecel, which is designed for people with blood types A or A/B only.
We expect to advance VX-017 into pivotal development in 2027. The FDA has granted Fast Track designation to
VX-017.
Investment in External Innovation
- In September, we completed the Crinetics Acquisition as described below.
Our Business Environment
In the first nine months of 2026, our total product revenues came primarily from the sale of our medicines for the
treatment of CF. Our CF strategy involves continuing to develop and obtain approval and reimbursement for treatment
regimens that will provide benefits to all people with CF and increasing the number of people with CF eligible and able to
receive our medicines. Outside of CF, we continue to advance the commercialization of CASGEVY for the treatment of SCD
and TDT, and JOURNAVX for the treatment of acute pain. We added PALSONIFY for the treatment of acromegaly to our
commercial portfolio in the third quarter of 2026 through the Crinetics Acquisition, and we are preparing for a potential
launch of povetacicept for the treatment of IgAN. In addition, we are advancing our pipeline of product candidates for the
treatment of serious diseases outside of CF, SCD, TDT, acute pain, and acromegaly.
Our strategy is to combine transformative advances in the understanding of causal human biology and the science of
therapeutics to discover and develop innovative medicines. This approach includes advancing multiple compounds or
therapies from each program, spanning multiple modalities, into early clinical trials to obtain patient data that can inform
selection of the most promising therapies for later-stage development, as well as to inform discovery and development
efforts. We aim to serially innovate in our disease areas of interest and follow our first-in-class therapies with potential best-
in-class candidates to provide durable clinical and commercial success.
In pursuit of new product candidates and therapies in specialty markets, we invest in research and development. We
believe that pursuing research in diverse areas allows us to balance the risks inherent in product development and may
provide product candidates that will form our pipeline in future years. To supplement our internal research programs, we
acquire technologies and programs and collaborate with biopharmaceutical and technology companies, leading academic
research institutions, government laboratories, foundations and other organizations, as needed, to advance research in our
areas of therapeutic interest and to access technologies needed to execute on our strategy.
Discovery and development of a new pharmaceutical or biological product is a difficult and lengthy process that requires
significant financial resources along with extensive technical and regulatory expertise. Across the industry, most potential
drug or biological products never progress into development, and most products that advance into development never receive
marketing approval. Our investments in product candidates are subject to considerable risks. We closely monitor our research
and development activities, and frequently evaluate our pipeline programs in light of new data and scientific, business and
commercial insights, with the objective of balancing risk and potential. This process can result in rapid changes in focus and
priorities as new information becomes available and as we gain additional understanding of our ongoing programs and
potential new programs, as well as those of our competitors. In addition, our product candidates must satisfy rigorous
standards of safety and efficacy before they can be approved for sale by regulatory authorities. Our analysis of data obtained
from nonclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could
delay, limit or prevent regulatory approval.
Our business also requires ensuring appropriate manufacturing and supply of our products. As we advance our product
candidates through clinical development toward commercialization and market and sell our approved products, we build and
maintain our supply chain and quality assurance resources. We rely on a global network of third parties, including some in
China, and our internal capabilities to manufacture and distribute our products for commercial sale and post-approval clinical
trials and to manufacture and distribute our product candidates for clinical trials. In addition to establishing supply chains for
each newly approved product, we adapt our supply chain for existing products to include additional formulations or to
increase scale of production for existing products as needed. The processes for biological and cell and genetic therapies can
be more complex than those required for small molecule drugs and require additional investments in different systems,
equipment, facilities and expertise. We are focused on ensuring the stability of the supply chains for our current products, as
well as for our pipeline programs.
Sales of our products depend, to a large degree, on the extent to which our products are reimbursed by third-party payors,
such as government health programs, commercial insurance and managed health care organizations. Reimbursement for our
products, including our potential pipeline therapies, cannot be assured and may take significant periods of time to obtain. We
dedicate substantial management and other resources to obtain and maintain appropriate levels of reimbursement for our
products from third-party payors, including governmental organizations in the U.S. and ex-U.S. markets. In the U.S., we
work with government and commercial payors to obtain and maintain appropriate levels of reimbursement for our medicines.
In ex-U.S. markets, we seek government reimbursement for our medicines on a country-by-country or region-by-region, as
required. This is necessary for each new medicine, as well as for label expansions for our current medicines. We expect to
continue to focus significant resources to expand and maintain reimbursement for our CF medicines, CASGEVY,
JOURNAVX, PALSONIFY, and, ultimately, our pipeline therapies, in U.S. and ex-U.S. markets.
Strategic Transactions
Acquisitions
As part of our business strategy, we seek to license or acquire technologies, products, product candidates and businesses
that are aligned with our corporate and research and development strategies and complement and advance our ongoing
research and development efforts. We have acquired multiple biotechnology companies over the last several years and expect
to continue to identify and evaluate such opportunities. The accounting for an acquisition can vary significantly based on
whether we conclude the relevant transaction represents a business combination or asset acquisition.
In 2024, we acquired Alpine Immune Sciences, Inc. (“Alpine”) and its lead molecule, povetacicept, for approximately
$5.0 billion. Povetacicept, has shown potential to treat multiple diseases or conditions and become a pipeline-in-a-product.
We accounted for the Alpine transaction as an asset acquisition because povetacicept represented substantially all of the fair
value of the gross assets that we acquired. As a result, $4.4 billion of the fair value attributed to povetacicept was expensed as
AIPR&D in 2024.
In September 2026, we acquired Crinetics, a publicly traded biotechnology company focused on discovering,
developing, and commercializing novel therapeutics for endocrine diseases and endocrine-related tumors, for $85.00 per
share in cash, equaling a total equity value of $10.0 billion, or $9.0 billion net of cash, cash equivalents and marketable
securities acquired. We funded the acquisition with our cash and cash equivalents and marketable securities, and $4.5 billion
of proceeds from the 2026 Term Loan. We have accounted for the Crinetics Acquisition as a business combination, which
resulted in $8.1 billion of additional intangible assets, as well as other assets acquired and liabilities assumed, recorded on our
condensed consolidated balance sheet. Please refer to Note C, “Business Combination,” for further information.
Collaboration and In-Licensing Arrangements
We enter into arrangements with third parties, including collaboration and licensing arrangements, for the development,
manufacture and commercialization of products, product candidates and other technologies that have the potential to
complement our ongoing research and development efforts.
We have collaboration agreements with a number of companies, including CRISPR Therapeutics AG (“CRISPR”) and
Entrada Therapeutics, Inc. (“Entrada”).
Generally, when we in-license a technology or product candidate, we make upfront payments to the collaborator, assume
the costs of the program and/or agree to make contingent payments, which could consist of milestone, royalty and option
payments. Most of these collaboration payments are expensed as AIPR&D because they were primarily attributable to
acquired in-process research and development for which there was no alternative future use. However, depending on many
factors, including the structure of the collaboration, the stage of development of the acquired technology, the significance of
the in-licensed product candidate to the collaborator’s operations and the other activities in which our collaborators are
engaged, the accounting for these transactions can vary significantly. We expect to continue to identify and evaluate
collaboration and licensing opportunities that may be similar to or different from the collaborations and licenses that we have
engaged in previously.
Acquired In-Process Research and Development Expenses
In the first nine months of 2026 and 2025, our AIPR&D included $62.5 million and $76.5 million, respectively, related
to upfront, contingent milestone, or other payments pursuant to our business development transactions, including the asset
acquisitions, collaborations, and licenses of third-party technologies described above. Please refer to Note B, “Collaboration,
License and Other Arrangements,” for further information regarding our asset acquisitions, collaborations and in-license
agreements.
Out-licensing Arrangements
We also have out-licensed certain development programs to collaborators who are leading the development or
commercialization of these programs, either globally or within certain geographic regions.
In January 2025 and June 2025, we entered into agreements with Zai Lab Limited (“Zai”) and Ono Pharmaceuticals Co.,
Ltd (“Ono”), respectively, for the development and commercialization of povetacicept in various Asian markets. Zai licensed
povetacicept for mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore, while Ono licensed
povetacicept for Japan and South Korea. Zai and Ono will help advance povetacicept clinical trials, and will be responsible
for obtaining marketing authorizations and commercialization activities, if povetacicept becomes an approved product, in
their licensed territories. We are eligible to receive certain future milestone payments and tiered royalties on future net sales
of povetacicept in these regions.
RESULTS OF OPERATIONS
Total Revenues
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | ||||||
| (in millions, except percentages) | |||||||||||
| TRIKAFTA/KAFTRIO | $2,436.9 | $2,653.6 | (8)% | $7,288.8 | $7,740.2 | (6)% | |||||
| ALYFTREK | 705.8 | 247.0 | 186% | 1,703.8 | 457.7 | 272% | |||||
| Other CF product revenues (1) | 130.5 | 139.3 | (6)% | 403.5 | 488.3 | (17)% | |||||
| Total CF product revenues, net | 3,273.2 | 3,039.9 | 8% | 9,396.1 | 8,686.2 | 8% | |||||
| CASGEVY | 99.2 | 16.9 | 487% | 218.5 | 61.5 | 255% | |||||
| JOURNAVX | 58.3 | 19.6 | 197% | 136.9 | 32.9 | 316% | |||||
| PALSONIFY | 10.1 | — | ** | 10.1 | — | ** | |||||
| Product revenues, net | 3,440.8 | 3,076.4 | 12% | 9,761.6 | 8,780.6 | 11% | |||||
| Other revenues | — | — | ** | — | 30.7 | ** | |||||
| Total revenues | $3,440.8 | $3,076.4 | 12% | $9,761.6 | $8,811.3 | 11% | |||||
| (1) Include KALYDECO, ORKAMBI and SYMDEKO/SYMKEVI. | ** Not meaningful |
Product Revenues, Net
In the third quarter and first nine months of 2026, our net product revenues increased 12% and 11%, as compared to the
third quarter and first nine months of 2025, respectively, primarily due to continued performance of our CF therapies and
growth from diversification into additional disease areas.
Other Revenues
Other revenues were $30.7 million in the nine months ended September 30, 2025, which included $20.6 million and
$10.0 million related to upfront payments received from our collaboration agreements with Ono Pharmaceuticals Co., Ltd.
and Zai Lab Limited, respectively, in the first half of 2025.
Total Revenues by Geographic Location
Our total revenues from the U.S. and from ex-U.S. markets were as follows:
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | ||||||
| (in millions, except percentages) | |||||||||||
| United States | $2,169.1 | $1,976.3 | 10% | $6,001.4 | $5,488.0 | 9% | |||||
| ex-U.S. | 1,271.7 | 1,100.1 | 16% | 3,760.2 | 3,323.3 | 13% | |||||
| Total revenues | $3,440.8 | $3,076.4 | 12% | $9,761.6 | $8,811.3 | 11% |
In the third quarter and first nine months of 2026, our U.S. total revenues increased 10% and 9%, as compared to the
third quarter and first nine months of 2025, respectively, primarily due to continued strong patient demand, including from
new initiations of ALYFTREK, and higher realized net prices in CF, and contributions from CASGEVY, JOURNAVX and
PALSONIFY.
In the third quarter and first nine months of 2026, our ex-U.S. total revenues increased 16% and 13%, as compared to the
third quarter and first nine months of 2025, respectively, primarily due to strong CF performance across multiple
geographies, including ALYFTREK uptake, increased CASGEVY product revenues, and favorable impacts from foreign
exchange.
Operating Costs and Expenses
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | ||||||
| (in millions, except percentages) | |||||||||||
| Cost of sales | $526.1 | $414.8 | 27% | $1,408.1 | $1,185.3 | 19% | |||||
| Research and development expenses | 1,320.6 | 977.7 | 35% | 3,276.0 | 2,935.8 | 12% | |||||
| Acquired in-process research and development expenses | 40.6 | 54.5 | (26)% | 62.5 | 76.5 | (18)% | |||||
| Selling, general and administrative expenses | 844.1 | 445.1 | 90% | 1,920.0 | 1,266.1 | 52% | |||||
| Intangible asset impairment charge | — | — | ** | — | 379.0 | ** | |||||
| Change in fair value of contingent consideration | (3.5) | (1.9) | ** | (2.9) | 1.2 | ** | |||||
| Total costs and expenses | $2,727.9 | $1,890.2 | 44% | $6,663.7 | $5,843.9 | 14% | |||||
| ** Not meaningful |
Cost of Sales
Our cost of sales primarily consists of third-party royalties payable on net sales of our CF products as well as the cost of
producing inventories. In the third quarter and first nine months of 2026, our cost of sales also included $15.3 million of
PALSONIFY intangible asset amortization expense and $5.4 million of PALSONIFY acquired inventory step-up expense
related to the month of September. In future quarters, the amount of intangible asset amortization expense and acquired
inventory step-up expenses will increase.
Our cost of sales as a percentage of our net product revenues increased to 15.3% and 14.4% in the third quarter and first
nine months of 2026, respectively, as compared to 13.5% in each of the third quarter and first nine months of 2025, as a result
of changes in product mix and the intangible asset amortization and acquired inventory step-up expense described above,
partially offset by a lower blended royalty rate for our CF medicines.
Pursuant to our agreement (the “CFF Agreement”) with the Cystic Fibrosis Foundation (the “CFF”), our tiered third-
party royalties on sales of ALYFTREK, TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, KALYDECO, and ORKAMBI,
calculated as a percentage of net sales, range from the single digits to the sub-teens, with lower royalties on sales of
ALYFTREK and TRIKAFTA/KAFTRIO than for our other products. The royalty burden associated with TRIKAFTA/
KAFTRIO is 9.33%, and our position is that the royalty burden associated with ALYFTREK is 4%. On October 10, 2025,
Royalty Pharma plc (“RP”), the third party to whom the CFF assigned its rights (and the CFF, which remains a party to the
CFF Agreement), initiated a confidential arbitration alleging the royalty burden on ALYFTREK is approximately 8%. RP is
seeking a declaratory judgment regarding the royalty burden on ALYFTREK as well as alleged unpaid royalties and other
alleged damages available under the CFF Agreement or applicable law, costs, expenses, attorneys’ fees, and interest. We
believe RP’s position is contrary to the plain terms of the CFF Agreement and intend to vigorously defend our position under
the CFF Agreement.
Research and Development Expenses
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | ||||||
| (in millions, except percentages) | |||||||||||
| Research expenses | $229.0 | $210.0 | 9% | $641.3 | $625.4 | 3% | |||||
| Development expenses | 1,091.6 | 767.7 | 42% | 2,634.7 | 2,310.4 | 14% | |||||
| Total research and development expenses | $1,320.6 | $977.7 | 35% | $3,276.0 | $2,935.8 | 12% |
Research Expenses
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | ||||||
| (in millions, except percentages) | |||||||||||
| Research Expenses: | |||||||||||
| Salary and benefits | $52.0 | $49.6 | 5% | $158.5 | $155.8 | 2% | |||||
| Stock-based compensation expense | 19.5 | 28.0 | (30)% | 61.9 | 72.8 | (15)% | |||||
| Compensation expense for cash-settled unvested Crinetics equity awards | 30.2 | — | ** | 30.2 | — | ** | |||||
| Outsourced services and other direct expenses | 63.3 | 72.2 | (12)% | 201.1 | 216.3 | (7)% | |||||
| Infrastructure costs | 64.0 | 60.2 | 6% | 189.6 | 180.5 | 5% | |||||
| Total research expenses | $229.0 | $210.0 | 9% | $641.3 | $625.4 | 3% | |||||
| ** Not meaningful |
Our research expenses include investment in our pipeline, including our cell and genetic therapy capabilities. Our
research expenses increased in the third quarter and first nine months of 2026 as compared to the third quarter and first nine
months of 2025, primarily due to compensation expense associated with cash-settled unvested equity awards related to the
Crinetics Acquisition. We expect to continue to invest in our research programs with a focus on creating transformative
medicines for serious diseases.
Development Expenses
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | ||||||
| (in millions, except percentages) | |||||||||||
| Development Expenses: | |||||||||||
| Salary and benefits | $222.2 | $182.2 | 22% | $628.9 | $565.4 | 11% | |||||
| Stock-based compensation expense | 82.5 | 88.0 | (6)% | 246.2 | 242.9 | 1% | |||||
| Compensation expense for cash-settled unvested Crinetics equity awards | 235.3 | — | ** | 235.3 | — | ** | |||||
| Outsourced services and other direct expenses | 409.2 | 364.7 | 12% | 1,103.1 | 1,116.9 | (1)% | |||||
| Infrastructure costs | 142.4 | 132.8 | 7% | 421.2 | 385.2 | 9% | |||||
| Total development expenses | $1,091.6 | $767.7 | 42% | $2,634.7 | $2,310.4 | 14% | |||||
| ** Not meaningful |
Our development expenses increased by 42% and 14% in the third quarter and first nine months of 2026 as compared to
the third quarter and first nine months of 2025, respectively, primarily due to $235.3 million of compensation expense
associated with cash-settled unvested equity awards related to the Crinetics Acquisition, which we recorded in the third
quarter of 2026, and increased outsourced services and other direct expenses. Our outsourced services and other direct
expenses were lower as compared to the first nine months of 2025 due to the discontinuation of certain clinical programs
during 2025.
As we have advanced our pipeline, we have invested in internal headcount and infrastructure to support multiple mid-
and late-stage clinical development programs, including our povetacicept, T1D, peripheral neuropathic pain and AMKD
programs. We expect to continue to invest in these programs, launch new products and advance our pipeline going forward.
Our research and development expenses include internal and external costs incurred for research and development of our
products and product candidates. We assign external costs of services provided to us by clinical research organizations and
other outsourced research by individual program. Our internal costs include salary and benefits, stock-based compensation
expense, laboratory supplies and other direct expenses and infrastructure costs, the majority of which are not assigned to
individual products or product candidates. Our stock-based compensation expenses, including those recorded as research and
development expenses, have historically fluctuated and are expected to continue to fluctuate from one period to another
primarily due to changes in the probability of achieving milestones associated with our performance-based awards.
Acquired In-Process Research and Development Expenses
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | ||||||
| (in millions, except percentages) | |||||||||||
| Acquired in-process research and development expenses | $40.6 | $54.5 | (26)% | $62.5 | $76.5 | (18)% |
AIPR&D in the third quarter and first nine months of 2026 and 2025 included various upfront and milestone payments
related to our collaboration and in-licensing arrangements. Our AIPR&D has historically fluctuated, and is expected to
continue to fluctuate, from one period to another due to upfront, contingent milestone, and other payments pursuant to our
existing and future business development transactions, including collaborations, licenses of third-party technologies, and
asset acquisitions.
Selling, General and Administrative Expenses
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||
| 2026 | 2025 | Change | 2026 | 2025 | Change | ||||||
| (in millions, except percentages) | |||||||||||
| Selling, general and administrative expenses | $844.1 | $445.1 | 90% | $1,920.0 | $1,266.1 | 52% |
In the third quarter and first nine months of 2026, our selling, general and administrative expenses increased by 90% and
52% as compared to the third quarter and first nine months of 2025, respectively, primarily due to a total of $203.0 million of
compensation expense for cash-settled unvested equity awards and transaction costs related to the Crinetics Acquisition in the
third quarter of 2026, increased internal headcount and commercial investment to support JOURNAVX and the anticipated
launch of povetacicept in IgAN. We expect to continue to invest in our commercialization capabilities in support of our
current and future product launches.
Intangible Asset Impairment Charge
In the first quarter of 2025, based on results from a Phase 1/2 clinical trial evaluating our VX-264 clinical program in
patients with T1D, we concluded that VX-264 will not be advancing further in clinical development. Based on this event, we
performed an interim impairment test on the fair value of our VX-264 indefinite-lived in-process research and development
asset. As a result, we recorded a full intangible asset impairment charge of $379.0 million associated with VX-264 in the first
quarter of 2025.
Non-Operating Income (Expense), Net
Interest Income
Our interest income decreased to $118.4 million in the third quarter of 2026 as compared to $125.7 million in the third
quarter of 2025, primarily due to reduced cash, cash equivalents and marketable securities following the Crinetics Acquisition
and decreased market rates. Our interest income decreased to $360.1 million in the first nine months of 2026 as compared to
$369.0 million in the first nine months of 2025, primarily due to decreased market rates partially offset by increased overall
cash, cash equivalents and marketable securities. We expect our future interest income to decrease as a result of our
decreased cash, cash equivalents and marketable securities following the Crinetics acquisition.
Interest Expense
Our interest expense increased to $36.0 million and $42.3 million in the third quarter and first nine months of 2026,
respectively, as compared to our interest expense of $3.3 million and $10.0 million in the third quarter and first nine months
of 2025, respectively, due to $4.5 billion that we borrowed on September 1, 2026 pursuant to the 2026 Term Loan and fees
associated with a debt commitment letter that preceded the 2026 Term Loan. Due to the amount that we borrowed in
September 2026, we expect our future interest expense to increase.
Other Income (Expense), Net
Other income (expense), net was expense of $11.9 million and income of $12.4 million in the third quarter and first nine
months of 2026, respectively, and were expenses of $9.8 million and $14.2 million in the third quarter and first nine months
of 2025, respectively. Our other income (expense), net in the third quarter and first nine months of 2026 was primarily due to
a realized gain associated with one of our strategic investments partially offset by realized losses on marketable securities
sales. Our other income (expense), net in the third quarter and first nine months of 2025 was primarily due to net unrealized
and realized gains and losses resulting from changes in the fair value of certain of our strategic equity investments and net
foreign currency exchange gains and losses.
Income Taxes
Our effective tax rate fluctuates from period to period due to the global nature of our operations. The factors that most
significantly impact our effective tax rate include changes in tax laws, excess tax benefits related to stock-based
compensation, variability in the amount and allocation of our taxable earnings among multiple jurisdictions, the amount and
characterization of our research and development expenses, the levels of certain deductions and credits, adjustments to the
value of our uncertain tax positions, acquisitions and third-party collaboration and licensing transactions.
Our effective tax rate of 18.8% in the first nine months of 2026 was lower than the U.S. statutory rate, primarily due to a
benefit from a research and development tax credit study that was completed in the third quarter of 2026, and excess tax
benefits related to stock-based compensation. Our effective tax rate of 16.6% in the first nine months of 2025 was lower than
the U.S. statutory rate, primarily due to a benefit from a research and development tax credit study that was completed in the
third quarter of 2025, excess tax benefits related to stock-based compensation, and increased utilization of foreign tax credits,
partially offset by changes in uncertain tax positions.
LIQUIDITY AND CAPITAL RESOURCES
The following table summarizes the components of our financial condition as of September 30, 2026 and December 31,
2025:
| As of September 30, 2026 | As of December 31, 2025 | Change | |||
| (in millions, except percentages) | |||||
| Cash, cash equivalents and marketable securities: | |||||
| Cash and cash equivalents | $4,979.3 | $5,084.8 | |||
| Marketable securities | 1,324.0 | 1,523.3 | |||
| Long-term marketable securities | 3,517.9 | 5,712.3 | |||
| Total cash, cash equivalents and marketable securities | $9,821.2 | $12,320.4 | (20)% | ||
| Working Capital: | |||||
| Total current assets | $11,686.3 | $11,201.0 | 4% | ||
| Total current liabilities | (5,000.3) | (3,861.2) | 30% | ||
| Total working capital | $6,686.0 | $7,339.8 | (9)% |
Working Capital
As of September 30, 2026, total working capital was $6.7 billion, which represented a decrease of $653.8 million, or 9%,
compared to December 31, 2025, primarily due to $1.0 billion of short-term debt related to the 2026 Term Loan and
decreased cash, cash equivalents and short-term marketable securities following the Crinetics Acquisition, partially offset by
increased inventories as a result of the Crinetics Acquisition.
Cash Flows
| Nine Months Ended September 30, | |||
| 2026 | 2025 | ||
| (in millions) | |||
| Net cash provided by (used in): | |||
| Operating activities | $3,196.6 | $3,133.4 | |
| Investing activities | $(6,578.3) | $(657.3) | |
| Financing activities | $3,331.4 | $(2,184.1) |
Operating Activities
Cash provided by operating activities increased to $3.2 billion in the first nine months of 2026, as compared to $3.1
billion in the first nine months of 2025, primarily due to less cash used for income taxes and inventory purchases, partially
offset by increased cash used to satisfy product revenue accruals.
Investing Activities
Cash used in investing activities was $6.6 billion in the first nine months of 2026, primarily related to $9.1 billion paid to
acquire Crinetics, net of cash and cash equivalents acquired, partially offset by $2.8 billion net sales and maturities of
available-for-sale debt securities. Cash used in investing activities was $657.3 million in the first nine months of 2025,
primarily related to net purchases of available-for-sale debt securities and purchases of property and equipment.
Financing Activities
Cash provided by financing activities was $3.3 billion in the first nine months of 2026, primarily due to $4.5 billion we
borrowed pursuant to our 2026 Term Loan partially offset by repurchases of our common stock pursuant to our share
repurchase programs. Cash used in financing activities was $2.2 billion in the first nine months of 2025, primarily related to
repurchases of our common stock pursuant to our share repurchase programs and payments in connection with common stock
withheld for employee tax obligations.
Sources and Uses of Liquidity
We intend to rely on our existing cash, cash equivalents and current marketable securities together with our operating
profitability as our primary source of liquidity. We expect that cash flows from our product sales together with our cash, cash
equivalents and current marketable securities will be sufficient to fund our operations for at least the next twelve months.
The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors,
including our future sales of currently marketed products, and the potential introduction of one or more new product
candidates to the market, our business development activities, and the number, breadth and cost of our research and
development programs.
Credit Facilities & Financing Strategy
In July 2026, we entered into the $4.5 billion 2026 Term Loan to finance a portion of the Crinetics Acquisition. We
borrowed the entire $4.5 billion in September 2026. Amounts due under the 2026 Term Loan are described below and can be
prepaid without penalty. We may also borrow up to a total of $500.0 million pursuant to a revolving credit facility that we
entered into in July 2026 (the “2026 Revolver”) and could repay and reborrow amounts under this revolving credit agreement
without penalty. Subject to certain conditions, we could request that the borrowing capacity be increased by an additional
$500.0 million, for a total of $1.0 billion. Covenants in the 2026 Term Loan and the 2026 Revolver could prohibit or limit
our ability to access these sources of liquidity.
Future Capital Requirements
We have significant future capital requirements, including:
- We are required to repay the $4.5 billion that we borrowed under the 2026 Term Loan as follows: $1.0 billion in
August 2027, $1.0 billion in September 2028, and $2.5 billion in August 2029.
- Expected operating expenses to conduct research and development activities, manufacture and commercialize our
existing and future products, and to operate our organization.
-
Cash that we pay for income taxes.
-
Royalties we pay related to sales of our CF products.
-
Facility, operating and finance lease obligations.
-
Firm purchase obligations related to our supply and manufacturing processes.
In addition, other potential significant future capital requirements may include:
- We have entered into certain agreements with third parties that include the funding of certain research, development,
manufacturing and commercialization efforts. Certain of our transactions, including collaborations, licensing
arrangements, and asset acquisitions, include the potential for future milestone and royalty payments by us upon the
achievement of pre-established developmental and regulatory targets and/or commercial targets. Other transactions
include the potential for future lease-related expenses and other costs. Our obligation to fund these research and
development and commercialization efforts and to pay these potential milestones, expenses and royalties is
contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause their
discontinuance. We may enter into additional agreements, including acquisitions, collaborations, licensing
arrangements and equity investments, which require additional capital.
- To the extent we borrow amounts under the 2026 Revolver, we would be required to repay any outstanding principal
amounts in July 2031.
- As of September 30, 2026, we had $2.5 billion remaining available under the share repurchase program that our
Board of Directors authorized in May 2025. The program does not have an expiration date and can be discontinued
at any time. We expect to fund the program through a combination of cash on hand and cash generated by
operations.
Other than the amounts borrowed under the 2026 Term Loan, there have not been any material changes to our future
capital requirements disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed
with the Securities and Exchange Commission, or SEC, on February 13, 2026.
We may also raise additional capital by borrowing under credit agreements, through public offerings or private
placements of our securities, or securing new collaborative agreements or other methods of financing. We will continue to
manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen
our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on
acceptable terms, if at all.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations are based upon our condensed
consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The
preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported
amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated
financial statements and the reported amounts of revenues and expenses during the reported periods. These items are
monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates
could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We
base our estimates on historical experience and various other assumptions that we believe to be reasonable under the
circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be
substantially accurate. During the nine months ended September 30, 2026, there were no material changes to our critical
accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed
with the SEC on February 13, 2026.
RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements, please refer to Note A, “Basis of Presentation and Accounting
Policies.”
Previous: Item 1. Financial Statements · Next: Item 3. Quantitative and Qualitative Disclosures About Market Risk